Previous studies in AIT looking for an association with the immune response genes in the HLA region have had conflicting findings. We studied 41 patients (33 females and 8 males) who had presented before the age of 21 with + thyroid microsomal antibodies (TMA), goiter and/or hypothyroidism without other endocrine disorders. The mean age of onset was similar in both sexes (11.72 vs 11.40 yrs respectively). Goiter was present at onset in 75%. All were studied for TMA by indirect immunofluorescence and for HLA-DR phenotypes. TMA were present in 64.1%. There was an increase in the frequency of HLA-DR3 (NS) and 4 (p = 0.05) and decrease of HLA-DR2 (NS) in the patients with AIT compared to 467 controls (C). The relative risk with HLA-DR 3 was 1.80 and, with HLA-DR 4, 1.99. The preventive fraction for HLA-DR 2 was 0.15. The frequency of DR phenotypes was similar between DR C AIT goitrous and non-goitrous AIT. Previous 1 20.6% 19.5% studies and our study in these families 2 28.9 17.1 suggested that the genetic predisposition to .3 22.1 34.1 AIT was not linked to the HLA region. The 4 30.2 46.3 association to certain HLA-DR alleles suggests 5 20.8 17.0 that these HLA-DR genes enhance the clinical 6 22.9 26.8 expression of AIT at an early age. On the 7 26.8 21.9 other hand, these patients with the HLA-DR 3 8 7.3 4.9 andlor 4 may represent a subgroup at higher 9 0.6 0.0 risk for developing other eltdocrine autoimmune 10 1.9 12.2 diseases associated with HLA-DR 3 or 4.
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INSULIN-LIKE GROWTH
Dispersed TI cells obtained from 21 day old hypox Sprague Dawley rats were cultured in serum-free medium in the absence and presence of increasing concentrations of LH, IGF-I or a combination of these hormones. The culture medium was changed every 48 hours and the androsterone (andro) concentration in the culture supernates, determined by RIA, was used as an index of TI cell differentiation.
In the absence of LH or IGF-I, TI cells produced less than 0.1 ng/ml of andro. In the presence of 0.1, 10, and 50 ng/ml of LH, andro synthesis increased progressively to peak levels of 0.4, 0.85 and 1.35 ng/ml, respectively. IGF-I alone did not increase andro synthesis above control values. However, 1, 10 and 100 ng/ml of IGF-I potentiated the andro response induced by 10 ng/ml of LH to peak levels of 32211, 2202115, and 435265 ng/ml (mean+SEM), respectively. Peak andro levels were obtained between 48 and 96 hours of culture.
Andro synthesis subsequently decreased, probably because of substrate depletion.
These results suggest that IGF-I plays a role in LH-induced differentiation of normal ovarian TI cells. We have previously shown that oral administration of clonidine (C) during one year period increases plasma somatomedin C (SM-C) levels, growth velocity and growth hormone (GH) response to C in prepubertal short children. Wc have now studied the effect of chronic administration of C on SM-C level and GH response to LDopa (DA) administration in three short children (aged 13.8 ? 1.8 yrs) with blunted CH response to DA administration but normal CH response to insulin-induced hypoglycemia and C.
C was administered orally in a single dose (0.15 mg/m2/body surface area) daily at night during a 3-month pcriod. The GH response to DA (250 mg) administration was determined before and one week after the treatment with C was terminated.
GH In an attempt to study the role of carbohydrate in the association of the subunits, deglycosylated hCG subunits were prepared by treatment with anhydrous HF-anisole then by incubation of hCG with 6M guanidine-tic1 and separation by a gel permeation HPLC in 0.1 M NH40Ac-HOAc, pH 4.0. The subunits of deglycosylated hCG reassociated tenfold faster than those of unmodified subunits. Studies on the reassociation of modified and unmodified subunits revealed that the deglycosylated *-subunit reassociated with either intact or deglycosylated Psubunit at a rate significantly faster than the intact r-subunit with intact or deglycosylated @-subunit. These results have demonstrated that carbohydrate moieties in the a-subunit dominate the reassociation behavior of hCG. Since hCG is implicated in precocious puberty, the elucidation of the functional properties of the two subunits of hCG and a potent antagonist like its deglycosylated derivative ma,y offer promising alternatives in the treatment of thls disorder. We investigated plasm osteocalcin levels before and during treatment with human growth hormone (GH) in 4 patients (pts.) with GH deficiency. GH deficiency was defined by Increase in serum GH<lO ngldl after stimulation with Insulin and L-Dopa and/or 24 hr. integrated 51<3.2 ng/dl. All 4 pts. had low bone density measured by radiographic photodensitometry as compared to normals for age and sex. All 4 p t s . were treated with a new GH produced by recdinant DNA and chemically identical to human GH at the dose of 0.1 n-g/Kg every other day for 6 mnths. Plasm osteocalcin was determined by RIA.
HUMAN GKWJM HOWONE ADMINISTRATION INCREASES
Epidermal growth factor (EGF) administration to very young animals causes growth retardation as well as precocious tooth eruption and eyelid opening. We previously demonstrated that EGF's ability to retard growth in the rat i s confined to the first 2 weeks of life and i s more pronounced in the immediate postnatal period (days 1-3). To investigate a possible mechanism through which EGF might alter somatic growth, we rneasured circulating concentrations of immunoreactive somato~nedin-C/insulinlike growth factor-I (Sm-C) 4 hours after a sin le injection of EGF. Rats (aged 1, 8, and 15 days) were given 500 nJg bw EGF and the Sm-C concentration measured after high pressure liquid chromatography of acidified sera. Osteocalcin (ng/ml) (mean+SD) The results show that exogenous EGF acutely reduces circulating Sm-C These data show that patients with GH deficiency have lcw levels at the ages where it also exerts its growth attenuating effect bone density and low Plasm osteocalcin levels. Treatment with (days 1 and 8) but not at I5 days of age, when the rat i s insensitive to the GH increases bone density and plasm levels of 0stmalcin. The growth-retarding property of EGF. These results are consistent with the GH induced increased in circulating osteocalcin suggests hypothesis that EGF, at this stage of development, prornotes stimulation of new bone fomtion and mineralization by GH.
differentiation at the expense of growth by altering production or secretion of Sm-C.
